Deutsch English Français

Contact

EP0662077

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP0662077

EP0662077 - CD27 LIGAND [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 21.12.2007 Database last updated on 03.10.2024
Most recent event Tooltip	01.01.2010	Lapse of the patent in a contracting state New state(s): LU	published on 03.02.2010 [2010/05]
Applicant(s)	For all designated states Immunex Corporation One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US
	[N/P]
Former [2007/04]	For all designated states IMMUNEX CORPORATION One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US
Former [1995/28]	For all designated states IMMUNEX CORPORATION 51 University Street Seattle Washington 98101 / US
Inventor(s)	01 / BECKMANN, M, Patricia 5454 Ragan Lane Poulsbo, Washington 98370 / US
	02 / GOODWIN, Raymond, G. 3322 - 8th Avenue West Seattle, WA 98119 / US
	03 / GIRI, Judith, G. 8020 Corliss Avenue North Seattle, WA 98103 / US
	04 / ARMITAGE, Richard, J. 5133 Eagle Harbor Drive Bainbridge Island, WA 98110 / US
	[1995/36]
Former [1995/28]	01 / BECKMANN, M., Patricia 15875 Nesika Bay Road Poulsbo, WA 98370 / US
	02 / GOODWIN, Raymond, G. 3322 - 8th Avenue West Seattle, WA 98119 / US
	03 / GIRI, Judith, G. 8020 Corliss Avenue North Seattle, WA 98103 / US
	04 / ARMITAGE, Richard, J. 5133 Eagle Harbor Drive Bainbridge Island, WA 98110 / US
Representative(s)	Cornish, Kristina Victoria Joy, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB
	[N/P]
Former [2000/31]	Cornish, Kristina Victoria Joy, et al Kilburn & Strode, 20 Red Lion Street London WC1R 4PJ / GB
Former [1995/28]	Chapman, Paul William, et al Kilburn & Strode, 30 John Street London WC1N 2DD / GB
Application number, filing date	93920446.7	01.09.1993
	[1995/28]
	WO1993US08223
Priority number, date	US19920941648	08.09.1992 Original published format: US 941648
	US19930106507	13.08.1993 Original published format: US 106507
	[1995/28]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO9405691
	Date:	17.03.1994
	Language:	EN
	[1994/07]
	Type:	A1 Application with search report
	No.:	EP0662077
	Date:	12.07.1995
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 17.03.1994 takes the place of the publication of the European patent application.
	[1995/28]
	Type:	B1 Patent specification
	No.:	EP0662077
	Date:	14.02.2007
	Language:	EN
	[2007/07]
Search report(s)	International search report - published on:	US	17.03.1994
	(Supplementary) European search report - dispatched on:	EP	22.11.1996
Classification	IPC:	C07H21/04, C07K14/52, C07K16/00, C12P21/06, C12N15/00	[2006/38]
	CPC:	C07K16/2875 (EP,US); C07K14/70575 (EP,US); C07K2317/34 (EP,US); Y10S930/14 (EP,US)
	Former IPC [1997/01]	C07H21/04, C07K14/52, C07K15/28, C12P21/06, C12N15/00
	Former IPC [1996/02]	C07H21/04, C07K14/00, C07K15/28, C12P21/06, C12N15/00
	Former IPC [1995/28]	C07H21/04, C07K13/00, C07K15/28, C12P21/06, C12N15/00
Designated contracting states	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE [1995/28]
Title	German:	CD27 LIGAND	[1995/28]
	English:	CD27 LIGAND	[1995/28]
	French:	LIGAND CD27	[1995/28]
Biological material	This application mentions deposited biological material, check the file for details
Entry into regional phase	10.03.1995	National basic fee paid
	10.03.1995	Search fee paid
	10.03.1995	Designation fee(s) paid
	10.03.1995	Examination fee paid
Examination procedure	17.03.1994	Request for preliminary examination filed International Preliminary Examining Authority: US
	10.03.1995	Examination requested [1995/28]
	02.11.1999	Despatch of a communication from the examining division (Time limit: M10)
	11.07.2000	Reply to a communication from the examining division
	16.01.2002	Despatch of a communication from the examining division (Time limit: M06)
	22.07.2002	Reply to a communication from the examining division
	08.01.2003	Observations by third parties
	16.10.2003	Despatch of a communication from the examining division (Time limit: M06)
	26.04.2004	Reply to a communication from the examining division
	14.03.2006	Despatch of a communication from the examining division (Time limit: M04)
	13.07.2006	Reply to a communication from the examining division
	01.09.2006	Communication of intention to grant the patent
	28.12.2006	Fee for grant paid
	28.12.2006	Fee for publishing/printing paid
Opposition(s)	15.11.2007	No opposition filed within time limit [2008/04]
Fees paid	Renewal fee
	08.09.1995	Renewal fee patent year 03
	12.09.1996	Renewal fee patent year 04
	10.09.1997	Renewal fee patent year 05
	09.09.1998	Renewal fee patent year 06
	13.09.1999	Renewal fee patent year 07
	13.09.2000	Renewal fee patent year 08
	12.09.2001	Renewal fee patent year 09
	12.09.2002	Renewal fee patent year 10
	12.09.2003	Renewal fee patent year 11
	14.09.2004	Renewal fee patent year 12
	14.09.2005	Renewal fee patent year 13
	11.09.2006	Renewal fee patent year 14
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	AT	14.02.2007
	BE	14.02.2007
	DK	14.02.2007
	NL	14.02.2007
	SE	14.05.2007
	GR	15.05.2007
	PT	16.07.2007
	LU	01.09.2007
	IE	03.09.2007
	MC	30.09.2007
	[2010/05]
Former [2008/45]	AT	14.02.2007
	BE	14.02.2007
	DK	14.02.2007
	NL	14.02.2007
	SE	14.05.2007
	GR	15.05.2007
	PT	16.07.2007
	IE	03.09.2007
	MC	30.09.2007
Former [2008/22]	AT	14.02.2007
	BE	14.02.2007
	DK	14.02.2007
	NL	14.02.2007
	SE	14.05.2007
	GR	15.05.2007
	PT	16.07.2007
	MC	30.09.2007
Former [2008/21]	AT	14.02.2007
	BE	14.02.2007
	DK	14.02.2007
	NL	14.02.2007
	SE	14.05.2007
	GR	15.05.2007
	PT	16.07.2007
Former [2008/05]	AT	14.02.2007
	BE	14.02.2007
	DK	14.02.2007
	NL	14.02.2007
	SE	14.05.2007
	PT	16.07.2007
Documents cited:	Search	[E]WO9410308 (IMMUNEX CORP [US]) [E] 9* Seq. id. n. 7. Summary of the invention*;
		[DY] - D. CAMERINI ET AL.,, "The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family", JOURNAL OF IMMUNOLOGY, (1991), vol. 147, no. 9, pages 3165 - 3169, XP002016796 [DY] 1-7 * the whole document *
		[DY] - R.J. ARMITAGE ET AL.,, "Molecular and biological characterization of a murine ligand for CD40", NATURE, LONDON, GB, (1992), vol. 357, pages 80 - 82, XP002016797 [DY] 1-7 * the whole document * DOI: http://dx.doi.org/10.1038/357080a0
		[PX] - R.G. GOODWIN ET AL.,, "Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor", CELL, (1993), vol. 73, pages 447 - 456, XP002016675 [PX] 1-7 * the whole document * DOI: http://dx.doi.org/10.1016/0092-8674(93)90133-B
		[T] - M.R. BOWMAN ET AL.,, "The cloning of CD70 and its identification as the ligand for CD27", JOURNAL OF IMMUNOLOGY, (1994), vol. 152, pages 1756 - 1761, XP002016676 [T] 1-7 * the whole document *
	International search	[Y]US4816567 (CABILLY SHMUEL [US], et al)
		[Y] - Nature, Volume 350, issued 04 April 1991, M.L. RIORDAN and J.C. MARTIN, "Oligonucleotide-Based Therapeutics", pages 442-443, entire document.
		[XY] - Eur. J. Immunol., Volume 18(5), issued May 1988, R.A.W. VAN LIER et al., "Anti-CD27 Monoclonal Antibodies Identify Two Functionally Distinct Subpopulations within the CD4+ T Cell Subset", pages 811-816, entire document.
		[Y] - EMBO Journal, Volume 8, Number 1, issued 1989, D.P. GEARING et al., "Expression Cloning of a Receptor for Human Granulocyte-Macrophage Colony-Stimulating Factor", pages 3667-3676, entire document.
		[Y] - Science, Volume 241, issued 29 July 1988, J.E. SIMS et al., "cDNA Expression Cloning of the IL-1 Receptor, a Member of the Immunoglobulin Superfamily", pages 585-589, entire document.
		[Y] - Science, Volume 241, issued 12 August 1988, K. YAMASAKI et al., "Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNbeta2) Receptor", pages 825-828, entire document.
		[Y] - J. Immunol., Volume 147(9), issued 01 November 1991, D. CAMERINI et al., "The T Cell Activation Antigen CD27 is a Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Gene Family", pages 3165-3169, entire document.
	Examination	US5573924
		- Declaration by coinventor Raymond G Goodwin filed for corresponding U.S. application, now U.S. patent No 5,573,924: dUnexpected difficulties in cloning CD27Ld
		- Stein H. et al., 1989, dCluster Report CD70d, in Knapp W et al., ed., Leucocyte Typing IV, p.446, Oxford University Press
		- HINTZEN RQ ET AL, "CD70 represents the human ligand for CD27", INTERNATIONAL IMMUNOLOGY, vol. 6, no. 3, pages 477 - 480, XP002956787
		- Office action response dated 22.12.1994 for corresponding US case (US 5,573,924)
		- PALOCZI K ET AL., "The Pattern of Activation Antigen Expression on T-Lymphocyte Subpopulation in Infectious Mononucleosis", HAEMATOLOGIA, vol. 24, no. 2, pages 83 - 90, XP009017756
		- PALOCZI K ET AL., "Detection of Activation Antigens on chronic Lymphocytic Leukaemia Cells", LEUKEMIA AND LYMPHOMA, vol. 3, no. 1, pages 31 - 36, XP009017755
		- PILERI S ET AL., "Lymphohistiocytic T-cell Lymphoma (Anaplastic Large Cell Lymphoma CD30+ /Ki-1+ with a High Content of Reactive Histiocytes)", HISTOPATHOLOGY, vol. 16, pages 383 - 391
	other	US5573924
		- STEIN H. ET AL, "A5 Cluster Report: CDw70", STEIN H. ET AL, KNAPP W. ET AL, LEUCOCYTE TYPING IV, OXFORD UNIVERSITY PRESS, (1989), pages 446 - 455, XP002956786
		- HINTZEN R.Q. ET AL, "CD70 represents the human ligand for CD27", INTERNATIONAL IMMUNOLOGY, (1994), vol. 6, no. 3, pages 477 - 480, XP002956787

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p